Fetuin-A as a Marker in Obesity and Type 2 Diabetes Mellitus

Diabete Type 2 Clinical Trial

Official title:

Study of Using Serum Fetuin-A as a Marker in Obesity and Type 2 Diabetes Mellitus

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04218305
• Other study ID #: fetuin-A as a marker
• Status: Completed
• Start date: January 1, 2016
• Est. completion date: March 1, 2016

Study information

• Verified date: January 2020
• Source: Minia University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The aim of this study is to assess the significance of serum fetuin-A as a marker of obesity and type 2 diabetes mellitus. We used multiple statistical approaches to determine that the fetuin-A level is correlated to body mass index (BMI) as well as random blood sugar in type 2 diabetic patients. Also, we found that there is a Positive correlation between the serum fetuin-A levels and the level of glycosylated hemoglobin (HbA1c) in diabetic patients.

Description:

The study was a case-control study. We started the study to be performed on eighty subjects divided into four groups:

The first group: include twenty subjects with type 2 diabetes mellitus The second group:

include twenty obese subjects whose body mass index is 30 or over The third group: include twenty obese subjects with type 2 diabetes mellitus The fourth group includes twenty apparently healthy subjects as control.

In this study, we concluded that:

1. Serum fetuin-A can be used as a biomarker and independent risk factor and marker for diagnosis of DM and DM has a detrimental effect on serum fetuin-A fetuin-A could be of relevance for the development of insulin resistance

2. Higher fetuin-A concentrations were associated with type 2 diabetes and insulin resistance

3. Increased serum fetuin-A levels constitute an independent marker of lipid profile.

4. fetuin-A may play a role in the pathogenesis of T2DM.

5. The inhibition of insulin receptor by fetuin-A may lead to increased lipolysis and efflux of free fatty acids from adipose tissue. This could explain associated dyslipidemia observed in type 2 diabetic patients in the present study.

Finally, our finding that high plasma fetuin-A levels predict the incidence of type 2 diabetes independently of other established risk factors supports the hypothesis that fetuin-A may play a role in the development of type 2 diabetes.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 400
• Est. completion date: March 1, 2016
• Est. primary completion date: February 1, 2016
• Gender: All
• Age group: 45 Years to 60 Years

Eligibility

Inclusion Criteria:

• • The study included obese and type 2 diabetic patients aged 45-60 years old. and control healthy adult persons

Exclusion Criteria:

• • Cardiac disease and Hypertensive disease

• Respiratory disease

• Renal disease

• GIT and Liver disease

• Rheumatologic disease

• Blood disease

• Endocrine disease except for type 2 diabetes mellitus

• All with a specific therapeutic drug history.

Related Conditions & MeSH terms

• Diabete Type 2
• Diabetes Mellitus
• Diabetes Mellitus, Type 2

Intervention

Diagnostic Test:
• Serum Level Of Fetuin A

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Minia University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	1- Study of human serum fetuin-A and whether it is involved in insulin resistance	2- To assess the significance of serum fetuin-A as a marker in obesity and type 2 diabetes mellitus	Baesline